Пиобактериофаг complex
Producer: Federal state unitary enterprise NPO Mikrogen Russia
Code of automatic telephone exchange: V03A
Pharm group: a href="javascript:if(confirm(%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57 \n\nThis file was not retrieved by Teleport Pro, because it is linked too far away from its Starting Address. If you increase the in-domain depth setting for the Starting Address, this file will be queued for retrieval. \n\nDo you want to open it from the server?%27))window.location=%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57%27" tppabs="medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57">Other different drugs
Release form: Liquid dosage forms. Solution for intake.
General characteristics. Structure:
Active ingredient: 20 ml of mix of sterile filtrates of fagolizat of stafilokokk, streptococci, enterococci, protea, клебсиелл (pneumonia and oxycurrent), pyocyanic and intestinal sticks.
Excipients: Chinosolum.
Pharmacological properties:
Pharmacodynamics. Пиобактериофаг complex liquid has ability to lyse specifically bacteria of stafilokokk, streptococci, enterococci, a protea, клебсиелл pneumonia and oxycurrent, pyocyanic and intestinal sticks.
Indications to use:
Treatment and prevention of the pyoinflammatory and intestinal diseases caused by stafilokokka, enterococci, streptococci, a pyocyanic stick, klebsiyella, pathogenic colibacillus of various serogroups, Proteus at internal, rectal and external use:
— diseases of an ear, throat, nose, respiratory tracts and lungs: inflammations of bosoms of a nose, middle ear, quinsy, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy;
— surgical infections: suppurations of wounds, burns, abscess, phlegmon, furuncles, anthrax, hydroadenitis, felons, paraproctitis, mastitis, bursitis, osteomyelitis;
— urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis;
— posttraumatic conjunctivitis, keratoconjunctivites, purulent helcomas and iridocyclites;
— enteral infections: gastroenterocolitis, cholecystitis, dysbacteriosis;
— generalized septic diseases;
— pyoinflammatory diseases of newborns: omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.;
— other diseases caused by bacteria of stafilokokk, streptococci, enterococci, a protea, клебсиелл pneumonia and oxycurrent, pyocyanic and intestinal sticks.
With the preventive purpose drug is used for processing of operational and svezheinfitsirovanny wounds, and also for prevention of intrahospital infections according to epidemic indications.
Important condition of an effective phagotherapy is preliminary definition of a fagochuvstvitelyyusta of the activator.
Route of administration and doses:
Treatment of pyoinflammatory diseases with the localized defeats has to be carried out at the same time as locally, and through a mouth, 7-20 days (according to clinical indications).
Depending on character of the center of an infection the bacteriophage is applied:
1. Locally in the form of irrigation, lotions and packing by a liquid phage in quantity to 200 ml depending on the sizes of an affected area. At abscesses the bacteriophage is entered into a center cavity after removal of pus by means of a puncture. The amount of the administered drug has to be slightly less than the volume of remote pus. At osteomyelitis later
the corresponding surgical treatment in a wound pour in a bacteriophage on 10-20 ml.
2. Introduction to cavities - pleural, joint and other limited cavities to 100 ml of a bacteriophage then leave a capillary drainage through which within several days repeatedly enter a bacteriophage.
3. At cystitis, pyelonephritises, uretrita drug is accepted inside. If the cavity of a bladder or a renal pelvis are trained, the bacteriophage is entered through tsistosty or nefrosty 1-2 once a day on 20-50 ml into a bladder and on 5-7 ml in a renal pelvis.
4. At pyoinflammatory gynecologic diseases the drug is administered in a cavity of a vagina, a uterus in a dose of 5-10 ml daily once.
5. At pyoinflammatory diseases of an ear, throat, nose the drug is administered in a dose 2-10 ml by 1-3 times a day. The bacteriophage is used for rinsing, by washings, instillations, introductions of the moistened turundas (leaving them for 1 hour).
6. At conjunctivitis and keratoconjunctivites drug is dug in on 2-3 drops of 4-5 times/days, at a purulent helcoma - on 4-5 drops, at purulent iridocyclites drug is used on 6-8 drops by each 3 h in combination with intake.
7. At treatment of stomatitises and chronic generalized paradontit drug 3-4 times a day in a dose use in the form of rinsings of an oral cavity 10-20 ml, and also introduction to parodontalny pockets of the turundas impregnated piobakteriofagy for 5-10 minutes.
8. At intestinal forms of a disease, diseases of internals, dysbacteriosis the bacteriophage is applied through a mouth and in an enema. Through a mouth 3 times/days on an empty stomach for 1 h to food give a bacteriophage. In the form of enemas appoint 1 times/days instead of one reception through a mouth.
The recommended drug dosages:
img src="http://medicalmeds.eu/img/data:image/png;base64,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" alt="" />
Use of bacteriophages does not exclude use of other antibacterial drugs. If before use of a bacteriophage chemical antiseptic agents were applied to treatment of wounds, the wound has to be washed carefully out sterile 0.9% by chloride sodium solution.
Use of a bacteriophage for children (up to 6 months). At sepsis, a coloenteritis of newborns, including premature children, the bacteriophage is applied in the form of high enemas (through a colonic tube or a catheter) by 2-3 times a day (see the tab.). In the absence of vomiting and vomiting use of drug through a mouth is possible. In this case it mixes up with breast milk. The combination rectal (in enemas) and peroral (through a mouth) drug uses is possible. Course of treatment of 5-15 days. At the recurrent course of a disease carrying out repeated courses of treatment is possible. For the purpose of prevention of sepsis and a coloenteritis at pre-natal infection or danger of developing of an intrahospital infection at newborn children the bacteriophage is applied in the form of enemas by 2 times a day within 5-7 days.
At treatment of omphalites, pyodermas, contaminated wounds use drug in the form of applications daily twice (the gauze napkin is moistened with a bacteriophage and impose on an umbilical wound or on an affected area of skin).
Features of use:
Use at pregnancy and feeding by a breast. Use of drug at pregnancy and during breastfeeding according to indications is possible.
Use for children. Use is possible according to the dosing mode.
Use for elderly patients. Use is possible according to the dosing mode.
Special instructions. Before the use the bottle with a liquid bacteriophage needs to be shaken up. At opacification not to use!
Influence on ability to driving of motor transport and to control of mechanisms. Data on possible influence of medicine on ability to manage vehicles, mechanisms are absent.
Side effects:
Are not established.
Interaction with other medicines:
Use of drug is possible in combination with other medicines, including with antibiotics.
Contraindications:
No.
Overdose:
Measures for assistance at overdose are not established.
Storage conditions:
Storage according to the joint venture 3.3.2.1248-03 at a temperature from 2 to 8 °C in dry, protected from light and the place, unavailable to children. Freezing is not allowed. A period of validity - 2 years. Transportation according to the joint venture 3.3.2.1248-03 at a temperature from 2 °C to 8 °C, is allowed transportation at a temperature from 9 °C to 25 °C no more than 1 month. Freezing is not allowed.
Issue conditions:
Without recipe
Packaging:
On 20 ml in bottles, on 8 bottles in cardboard packs.